Table 1.
Characteristic | All subjects (n = 36) | Survivors (n = 15) | Nonsurvivors (n = 21) |
---|---|---|---|
Age at initiation, median (range), days | 44. (1–359) | 162 (1–359) | 27. (1–321) |
Length of follow-up, median (range), days | NA | 1,219.5 (585–4,283) | NA |
Ventilator use | 36. (100) | 15 (100) | 21. (100) |
ECMO use | 11. (30.6) | 4 (36) | 7. (33.3) |
Medications | |||
Nitric oxide | 30. (83.3) | 12 (80) | 18. (85.7) |
Diuretics | 25. (69.4) | 9 (60) | 16. (76.2) |
Dopamine | 16. (44.4) | 2 (13.3) | 14. (66.7) |
Sildenafil | 15. (41.7) | 5 (33.3) | 10. (47.6) |
Milrinone | 6. (16.7) | 2 (13.3) | 4. (19.0) |
Dobutamine | 1. (2.8) | 0 (0) | 1. (4.8) |
Data are no. (%), unless otherwise indicated. NA: not applicable; ECMO: extracorporeal membrane oxygenation.